Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Small Cell Lung Cancer

Inclusion Criteria:

• Histologically or cytologically proven small cell lung cancer
• Patients currently receiving 4-6 cycles of chemotherapy regimen with VP-16 and a platinum-based drug as first-line therapy in the absence of disease progression
• Age between 18-75
• Performance status ≤2
• No uncontrolled metabolic disease, infection, and neurological disorders
• No congestive heart failure, severe arrhythmia, and coronal atherosclerosis heart disease
• Life expectancy more than three months.
• Without contraindication of immunotherapy with autologous cytokine-induced killer cells
• No other malignancies
• Signed study-specific consent form prior to study entry

Exclusion Criteria:

• Patients receiving other anti-tumor therapy (like thermotherapy)
• Pregnant or lactating women
• Allergy or unacceptable toxicity of immunotherapy with autologous cytokine-induced killer cells
• Uncontrolled mental disorder
• Patient having acute hepatitis virus infection, active tuberculosis, or other acute infectious diseases